Navigation Links
Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO

Industry Veteran Combines Expertise with Passion for Healthcare

MIAMI, Nov. 14 /PRNewswire/ -- Novis Pharmaceuticals, a leading distributor of biotherapeutic products to healthcare providers funded by MTS Health Investors and Oaktree Capital Management, L.P., announced today the appointment of Thomas E. Burke III to the position of President and CEO. Tom brings over 30 years of distribution experience to Novis Pharmaceuticals, with extensive functional expertise in sales, sales management, operations and the management and development of people.

As the Group Vice-President of Cardinal Health, Integrated Provider Solutions, Tom had Northeast responsibility for five businesses: Distribution, Laboratory, Manufactured Products, Pyxis Supply and Presource which generated $1.4 billion in revenue. He also held several executive level positions in other Cardinal Health companies, including serving as President of the Southeast and the Northeast Regions of Cardinal Health, Medical Products and Services, each with revenue in excess of $1.3 billion and consisting of seven distribution facilities. In addition, Tom was responsible for a two-facility region that represented $3.1 billion in pharmaceutical sales for Cardinal Distribution/Aurora, Illinois Division when he held the position of Regional Vice President.

Jay J. Levin, Executive Chairman of Novis Pharmaceuticals, said, "Novis is committed to providing industry-leading standards of quality and exceptional service to our customers. We were looking for an innovative and visionary leader who not only had the depth of functional expertise to grow the business and to develop our people, but also the personal integrity and character to build sustainable and mutually-rewarding relationships with our manufacturers, our supply chain partners, and our customers."

"I am honored to have worked my entire career in an industry that makes a difference in patients' lives," added Tom Burke. "In order for Novis Pharmaceuticals to succeed, we know we must deliver flawlessly every time. We know that we can save a life every time one of our products is used. There is no room for error."

For more information about Novis Pharmaceuticals, please visit

About NOVIS Pharmaceuticals

Novis Pharmaceuticals is a leading national distributor of some of the world's leading plasma-derived products such as albumin, immune globulin, hyperimmunes and anti-hemophilic Factors VII, VIII and IX. Hospitals, home infusion therapy companies and other healthcare providers use these biotherapeutics to treat trauma, autoimmune conditions, immune deficiencies, infectious diseases, bleeding disorders, and other life-threatening conditions.

About MTS

MTS Health Investors, LLC, located in New York, is a healthcare private equity firm that makes equity investments in the buyout, recapitalization or growth financing of healthcare operating companies. MTS focuses on businesses that operate in services sectors of the healthcare industry - managed care/health insurance, providers of healthcare services, distributors of medical products and providers of outsourced services to the healthcare industry. The firm also invests in manufacturers of low-technology medical products. For further information, please visit:

About Oaktree Capital Management, L.P.

Oaktree Capital Management was founded in 1995 and is headquartered in Los Angeles, California. It is an independent investment management firm with over $52 billion of assets under management in specialized investment strategies. These strategies include private equity, distressed debt, high yield bonds, convertible securities, Asian and emerging market equities, real estate, and mezzanine debt. Oaktree's institutional clients include Fortune 100 companies, large public pension funds, university endowments, private foundations and high net worth individuals. In addition to Los Angeles, Oaktree has offices in New York, Stamford, Tokyo, Singapore, Hong Kong, Beijing, London, Frankfurt and, through fund affiliates, Luxembourg.

SOURCE Novis Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Renovis Announces Management Changes
2. Inovis Sponsors ASC X12 Conference, Exhibits BizManager and Secure Link
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, ... evaluating the efficacy of its product and its disinfection protocol. This study is taking ... 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bunion ... in an early celebration of the early holiday shopping season. Starting Wednesday November ... (normally $33.95 ea). Black Friday promotional pricing is in addition to any automatic ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... new market research report "Spine Biologics Market by Product Type ... Type (Anterior Cervical Discectomy and Fusion, Posterior Lumbar Interbody Fusion), ... by MarketsandMarkets, the global market was valued at $1.90 Billion ... 2020, at a CAGR of 4.4% during the forecast period ...
Breaking Medicine Technology: